Drugs / Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05706324 | Jun → Dec 2023 | COVID-19 | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05706324 ↗ |
| Known as | RCVi | “In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine...” NCT05706324 ↗ |
| Modality | Vaccine | “investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi)” NCT05706324 ↗ |
| Route | Inhaled | “0.2mL/dose, Inhalation using a nebulizer” NCT05706324 ↗ |